Skip to main content
Premium Trial:

Request an Annual Quote

News Scan: Jan 23, 2009

Premium

CRi, VisEn Ink Deal; CRi to Distribute VisEn's Labels in North America

Cambridge Research & Instrumentation and VisEn Medical announced this week that they have signed a non-exclusive agreement that allows CRi to distribute VisEn's proprietary portfolio of fluorescent imaging agents and labels in North America.

VisEn's proprietary imaging agents and labels are designed to provide a range of biologically specific imaging readouts in vivo. VisEn now offers over 25 different fluorescence molecular agents for imaging disease-associated biologic targets, processes, and pathways in vivo, with several more new agents expected for launch in 2009.

Applications of the VisEn agents include imaging disease progression and therapeutic response in real time in oncology, inflammation, cardiovascular disease, bone disease, and pulmonary diseases, all in the context of the living animal. VisEn also offers specialized in vivo agent labeling platforms, including its proprietary VivoTag fluorescence labeling dyes for custom in vivo agent development, and its NanoSpark in vivo labeling nanoparticles.

VisEn's agents and labels are designed to be compatible with a range of fluorescence imaging systems, including the CRi Maestro system.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.